MedTrace Logo

Study to Investigate the Effects of AZD6140 in Patients With Renal Impairment and in Healthy Volunteers

NCT00733265 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2010-12-03

No results posted yet for this study

Summary

The main purpose of this study is to examine how AZD6140 affects patients with severe kidney disease compared to volunteers with normal kidneys. Subjects in the study will receive one dose of AZD6140.

Conditions

  • Renal Impairment

Interventions

DRUG

AZD6140

single oral dose

Sponsors & Collaborators

Principal Investigators

  • Kathleen Butler, MD · AstraZeneca

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2008-09-30
Completion
2008-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00733265 on ClinicalTrials.gov